Crystal-Growth Formation Processes of Hnamp2o7 Crystals under Hydrothermal Conditions by Byrappa, K. & Dutt, B. U.
RESEARCH ARTICLE
Rapid Quantitative Assay of Albendazole in 
Bulk Drug and Pharmaceuticals by UHPLC
Chemical Sciences 
Journal, Vol. 2013: 
CSJ-113








Co-Publisher: OMICS Group, www.omicsonline.org http://astonjournals.com/csj
Rapid Quantitative Assay of Albendazole in Bulk Drug  
and Pharmaceuticals by UHPLC
Nagaraju Swamy, Kanakapura Basavaiah*, Vamsi K Penmatsa,  
Kanakapura B Vinay, Kudige N Prashanth
Department of Chemistry, University of Mysore, Manasagangothri,  
Mysore 570 006, Karnataka, India.
*Correspondence: kanakapurabasavaiah@gmail.com
Accepted: Jul 6, 2013; Published: Oct 8, 2013
Abstract
A simple, rapid, precise, isocratic and stability indicating ultra-high performance liquid chromatography (UHPLC) method was 
developed and validated for the determination of albendazole (ALB) in bulk drug and its dosage forms. The chromatographic 
separation of the drug was achieved on an Agilent Zorbax Extend C-18 (50 3 4.6 mm, 1.8 mm) UHPLC column with mobile phase 
consisting of a mixture of orthophosphoric acid buffer and acetonitrile (50:50 v/v). The eluted compound was detected at 295 nm 
with a UV detector. The newly developed method was validated according to the International Conference on Harmonisation (ICH) 
guidelines with respect to linearity, limit of detection (LOD), limit of quantification (LOQ), accuracy, precision, robustness and 
ruggedness. The standard curve of mean peak area versus concentration showed an excellent linearity over a concentration 
range 0.24–60 mg mL21 ALB with regression coefficient (r) of 0.9998. The LOD (S/N 5 3) and LOQ signal-to-noise (S/N 5 10) 
were 0.01 and 0.04 mg mL21, respectively. ALB active substance was subjected to forced degradation to demonstrate the stability 
indicating power of the UHPLC method. Acidic, basic, oxidative, hydrolytic, thermal and photolytic degradation were used to 
assess the stability of the method. Peak purity index was checked using UV detection to demonstrate the specificity and stability 
indicating nature of the method. 
Keywords: Albendazole; UHPLC; stability indicating; assay; pharmaceuticals.
1. Introduction
Albendazole (ALB) (Figure 1), chemically known as methyl [5-(propylthio)-1H-benzimidazol-2-yl] carbamate [1], is 
widely used as an anthelmintic having a wide spectrum of activity [2]. The drug is official in British Pharmacopoeia [3], 
which describes a potentiometric titration with perchloric acid in formic acid–acetic acid medium. Quantitative 
determination of ALB in formulations has received wide attention and several methods have been reported, and 
include titrimetry in non-aqueous medium [4, 5], redox titrimetry [6–12], UV-spectrophotometry [13–17], spectro-
fluorimetry [18, 19], visible spectrophotometry [4, 6, 7, 10–12, 20–27], voltammetry [28–30], high performance liquid 
chromatography (HPLC) [31–35], high performance thin layer chromatography (HPTLC) [36, 37] and ultra perfor-
mance liquid chromatography (UPLC) [38].











Recently, ultra-high performance liquid chromatography (UHPLC) has been considered to be a new direc-
tion of liquid chromatography [39–48], stability indicating assays using the approach to stress testing enshrined in 
International Conference on Harmonization (ICH) guideline Q2A (R2) [49]. The principle advantages reported for 
UHPLC are the increase in the signal-to-noise ratio (S/N) (narrower peaks), a reduction in the analysis time and 
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toxicological and clinical analysis for increasing analysis throughout and reducing analysis costs. UPLC system is 
designed in a special way to withstand high system back-pressures. Special analytical UHPLC columns, Agilent Zorbax 
Extend C-18 packed with 1.8 mm particles are used in connection with this system. These small particles lead to 
drastic increases of the resolution, sensitivity and speed of analysis.
UHPLC has earlier been used for the assay of ALB in turkey blood plasma [38] and is not stability indicating 
despite its many fold advantages. The aim of this work was to develop a rapid, precise, accurate and validated stabil-
ity indicating UHPLC method for the determination of ALB in bulk drug and pharmaceutical formulations. This was 
accomplished with a Waters Acquity UHPLC system and Agilent Zorbax Extend C-18 (50 3 4.6 mm, 1.8 mm). The 
stability indicating power of the method was established by comparing the chromatograms obtained under optimized 
conditions before forced degradation with those after degradation via acidic, basic, hydrolytic, oxidative, thermal and 
photolytic stress conditions.
2. Methods
2.1. Materials and reagents
Pharmaceutical grade ALB (99.7% pure) was received as a gift from Cipla Pvt. Ltd., Mumbai, Maharashtra, India and 
used as received. Alworm-400 (Medopharm Pvt. Ltd., Malur, Karnataka, India), ABD-400 (Intas Pharmaceuticals Ltd., 
Ahmedabad, Gujarat, India) and Bandy-400 (Mankind Pharma Ltd., New Delhi, India) tablets were purchased from 
local commercial sources.
HPLC grade acetonitrile and methanol were purchased from Merck Pvt. Ltd., Mumbai, Maharashtra, India. 
Orthophosphoric acid and triethyl amine were from Qualigens Fine Chemicals, Mumbai, Maharashtra, India. Doubly 
distilled water was used throughout the investigation. 
2.2. Chromatographic conditions and equipments
UHPLC was performed using a Waters Acquity system equipped with binary solvent delivery pump, an auto sampler 
and tunable UV (TUV) detector. The output signal was monitored and processed using Empower-2 software. The 
chromatographic column used was Agilent Zorbax Extend C-18 (50 3 4.6 mm, 1.8 mm). Isocratic elution process 
was adopted throughout the analysis.
2.3. Mobile phase preparation
Two mL of orthophosphoric acid was dissolved in 1000 mL of water and pH adjusted to 7.0 using triethylamine. 
A 50 mL portion of this resulting buffer was mixed with 50 mL acetonitrile, shaken well and filtered using 0.22 mm 
nylon membrane filter. Methanol:water (50:50 v/v) was used as diluent in all subsequent preparations of the sample.
2.4. Instrumental parameters
The isocratic flow rate of mobile phase was maintained at 0.5 mL min21. The column temperature was adjusted to 
30C. The injection volume was 4 mL. Eluted sample was monitored at 295 nm and the run time was 5 min. The reten-
tion time of the sample was about 2.219 min.
2.5. Preparation of standard solution
To prepare a stock standard solution of ALB (100 mg mL21), 10 mg of pure drug was accurately weighed into a 100 mL 
volumetric flask and 50 mL methanol was added. The content was sonicated for complete dissolution of ALB, made 
up to the mark with water and filtered through a 0.22 mm nylon membrane filter. 
2.6. Assay procedures 
2.6.1. Procedure for preparation of calibration curve
Working solutions containing 0.24–60 mg mL21 ALB were prepared by serial dilutions of aliquots of the stock solution. 
Aliquots of 4 mL were injected (six injections) and eluted with the mobile phase under the reported chromatographic 
conditions. The average peak area versus the concentration of ALB in mg mL21 was plotted.
2.6.2. Procedure for tablets
Ten tablets each containing 400 mg of ALB were weighed and transferred into a clean, dry mortar and powdered. 
Portion of the powdered tablet equivalent to 10 mg of ALB was transferred into a 100 mL volumetric flask and 50 mL 
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of the methanol was added. The content was sonicated for 20 min to achieve complete dissolution of ALB and 
the solution was then diluted to volume with water to yield a concentration of 100 mg mL21 and filtered through 
0.22 mm nylon membrane filter. The solution obtained was injected into the UHPLC column after appropriate dilution 
with diluent. 
2.6.3. Sample preparation for forced degradation
A 2 mL of 100 mg mL21 standard ALB was transferred into four different 10 mL volumetric flasks and added 2 mL of 
5 M HCl, 5 M NaOH or 5% H2O2 and water separately, and the flasks were heated for 3 h on a water bath maintained 
at 80C. Then the solutions were cooled and neutralized by adding base or acid, the volume in each flask was brought 
to the mark with diluent, and the appropriate volume (4 mL) was injected for analysis. Solid state thermal degradation 
was carried out by exposing pure drug to dry heat at 105C for 24 h. For photolytic degradation studies, pure drug 
in solid state was exposed to 1200 K flux hours in a photo stability chamber. The sample after exposure to heat and 
light was used to prepare 100 mg mL21 solutions in diluent and the chromatographic procedure was followed and 
peak purity was checked for ALB using TUV detector and Empower-2 software in the degraded samples and control 
sample to verify the co-eluted peaks of degradation products and excipients.
2.6.4. Method validation
Linearity: To evaluate the linearity of the method, solutions of seven concentrations (0.24, 5.0, 10.0, 20.0, 30.0, 40.0 
and 60 µg mL21) were prepared using ALB working standard and 4 mL injected in triplicates. The calibration curve was 
plotted for peak area of ALB against the corresponding concentration using linear regression analysis. The y-intercept 
and correlation coefficient were calculated.
LOD and LOQ: The LOD and LOQ were predicted from the separate linearity study conducted at 0.24–60 µg mL21 
(0.24, 5.0, 10.0, 20.0, 30.0, 40.0 and 60 µg mL21) levels. The sample solutions were prepared at predicted LOD and 
LOQ levels and the percentage relative standard deviation (RSD) for area counts for six replicates at these levels 
were calculated.
Accuracy and precision: Six injections, of three different concentrations (15, 30 and 45 µg mL21) were given 
on the same day and the values of RSD were calculated to determine intra-day precision. These studies were also 
repeated on different days to determine inter-day precision.
Robustness: To determine the robustness of the method the experimental conditions were deliberately changed. 
The column oven temperature (30 6 2C), mobile phase composition (40:60, 50:50 and 60:40; acetonitrile:buffer 
(v/v)), flow rate of the mobile phase (0.5 6 0.05 mL min21) and detection wavelength (295 6 2 nm) were the varied 
parameters. In each case the %RSD values were calculated for the obtained peak area. The number theoretical plates 
and tailing factors were compared with those obtained under the optimized conditions.
Ruggedness: The study was performed on the same day and on three different days by three different analysts for 
three different concentrations of ALB (triplicates injections). The area, retention time, theoretical plates and tailing 
factor obtained for fixed concentration of drug was compared with that of the optimized one. The relative standard 
deviation values were evaluated for each parameter.
Solution stability and mobile phase stability: Stability of the ALB solution was evaluated by injecting the sample 
solution into the chromatographic system at different time interval. The peak area was recorded in the time interval 
0, 12 and 24 h and the RSD values were calculated. Freshly prepared solution was injected at the same time intervals 
for mobile phase stability (0, 12 and 24 h) and RSD values of the peak areas were calculated. 
3. Results and Discussion
3.1. Optimization of chromatographic conditions
The lmax was determined for the ALB using working standard (100 µg mL21) solution and was found to be 295 nm. 
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acetonitrile was selected as mobile phase B, as it can overcome background noise and is useful for the stable baseline 
and sensitive detection of ALB at 295 nm. Different trials were made with stationary phase C-18, phenyl and C-8 
for good peak shape and retention. Finally good peak shape and retention were found with stationary phase Agilent 
Zorbax Extend C-18 (50 3 4.6 mm, 1.8 mm) column. Flow rate was fi xed to 0.5 mL min21 and the peak response was 
monitored at l of 295 nm. After forced degradation studies, the mobile phases were fi xed as 50% of orthophosphoric 
acid buffer and 50% of acetonitrile for better separation of individual degradation products and ALB. The pH of the 
mobile phase optimized to 7.0, was robust for retentions of ALB and its degradation peaks. 
3.2. Results of forced degradation study
No degradation products were obtained in hydrolytic, thermal and photolytic conditions. Slight degradation in acidic 
medium and complete degradation in basic and peroxide medium were observed. The chromatograms of degraded 
samples are given in Figure 2. The peak purity index for ALB in all degradation samples was found to be positive. The 
three point peak purity values were found to be not less than 0.999, which proves that the peak was homogeneous, 
without co-eluted peaks of degradation products and excipients. The proposed method was found to be specifi c, 
selective and suitable for the determination of ALB in the presence of its possible degradation products, which can 
form during the storage of the active substance and tablet forms.
Figure 2: Chromatograms of ALB after forced degradation (20 µg mL21) 
(1) acid  degradation, (2) base degradation, (3) oxidative degradation, (4) thermal degradation, 
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Linearity: Seven-point calibration curves were obtained in a concentration range 0.24–60 mg mL21 for ALB. The 
correlation coefficient and y-intercept were found to be 0.9998 and 21884.42, respectively. The linearity data is given 
in Table 1.
LOD and LOQ: The LOD and LOQ were found to be 0.01 and 0.04 mg mL21, respectively. The %RSD for six 
replicates at LOD and LOQ level were found to be 1.96 and 2.84, respectively. 
Table 1:   Linearity and regression parameters with precision data.
Parameters Values
Linearity (mg mL21) 0.24–60
LOD (mg mL21) 0.01
LOQ (mg mL21) 0.04
Correlation coeffi cient (r) 0.9998
Intercept (a) 21884.42
Slope (b) 21921.5985
Standard deviation of intercept (Sa) 12918.21
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Accuracy: The mean percentage found for triplicate injections of the test concentration level was found to be 
between 98.33 and 101.8. The results of accuracy are given in Table 2.





(mg mL21) % ALB found REa (%)
ALB found 
(mg mL21) % ALB found REa (%)
15 14.84 98.33 1.07 14.81 98.73 1.26
30 29.54 98.47 1.53 30.54 101.8 1.80
45 44.68 99.29 0.71 44.39 98.64 1.35
aRelative error.
Precision: The %RSD values for system precision, method precision and intermediate precision were found and 
they prove the excellent precision of the method compiled in Table 3.




Intra-day precision (n 5 7) Inter-day precision (n 5 5)



















15 340642 6 1409 0.41 2.238 6 0.020 0.89 340563 6 2284 0.67 2.243 6 0.021 0.94
30 654421 6 1932 0.29 2.240 6 0.022 0.98 654987 6 6767 1.03 2.241 6 0.019 0.85
45 997349 6 1549 0.16 2.239 6 0.019 0.85 997687 6 3786 0.38 2.245 6 0.021 0.94
aRelative standard deviation based on peak area. 
bRelative standard deviation based on retention time.
Robustness and ruggedness: The system suitability parameters were found to be USP plate count more than 
6000, USP tailing less than 1.1, %RSD for system precision less than 2% and signal-to-noise ratio (S/N) more than 10. 
The selectivity of the ALB peak was also not affected by varied conditions, which confirms robustness of the method. 
In method ruggedness, different columns (same lot), at different day by different analyst were performed. The results 
are summarized in Tables 4 and 5.





















(n 5 3) 447196 6 1409
0.32 2.239 6 0.02 0.89 6616 6 119.63 1.81 1.11 6 0.004 0.36
Column
(n 5 3) 444454 6 1418
0.32 2.236 6 0.03 1.34 6588 6 120.33 1.83 1.08 6 0.005 0.46
*Mean value of three determinations.
















Mean  tailing 
 factor 6 SD*
RSD 
(%)





435090 6 5891 1.35 2.247 6 0.016 0.71 6459 6 120 1.86 1.07 6 0.006 0.56
Flow rate 0.5 6 0.05 min 438605 6 5134 1.17 2.236 6 0.017 0.76 6449 6 113 1.75 1.06 6 0.005 0.47
Wavelength 295 6 2 nm 439656 6 5127 1.16 2.257 6 0.015 0.66 6441 6 116 1.80 1.05 6 0.004 0.38
*Mean value of three determinations.
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Solution stability and mobile phase stability: At the specified time interval, %RSD for the peak area obtained 
from drug solution stability and mobile phase stability were within 1%. This shows no significant change in the elution 
of the peak and its system suitability criteria (%RSD, tailing factor, theoretical plates). The results also confirmed that 
the standard solution of drug and mobile phase were stable at least for 24 hours during the assay performance. The 
results are compiled in Tables 6 and 7. 
























445919 444559 6 1342 0.30 2.22 2.237 6 0.01 0.447 6588 6 62.42 0.95 1.09 6 0.005 0.46
444523 2.25
*Mean value of three determinations, chromatograms recorded at 0, 12 and 24 h (ALB 20 mg mL21).
























445919 444693 6 1072 0.24 2.23 2.24 6 0.01 0.446 6588 6 59.23 0.90 1.08 6 0.005 0.46
444223 2.25
*Mean value of three determinations, chromatograms recorded at 0, 12 and 24 h (ALB 20 mg mL21).
Selectivity: Selectivity of the method was evaluated by injecting the mobile phase, placebo blank, pure drug solution 
and tablet extract. No peaks were observed for mobile phase and placebo blank and no extra peaks were observed 
for tablet extracts and synthetic mixture (Figures 3 and 4).
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4. Application to tablet
A 100 mg mL21 solution of tablets was prepared as per ‘procedure for tablets’ and injected in triplicate to the UHPLC 
system after suitable dilution. The mean peak area of the tablets extract was found to be equivalent to the pure drug 
and the results were compared with those of an official method [3] which describes a potentiometric titration with 
perchloric acid in formic acid–acetic acid medium. The accuracy and precision of the proposed method was further 
evaluated by applying Student’s t-test and variance ratio F-test, respectively. The t- and F-values at 95% confidence 
level did not exceed the tabulated values and this further confirms that there is no significant difference between the 
official and proposed methods. Table 8 illustrates the results obtained from this study.
Table 8:   Results of analysis of tablets by the proposed methods and statistical comparison of the  




% ALB foundd 6 SD
t-value F-valueOfficial method Proposed method
Alworm-400a 400    99.8 6 0.68 99.54 6 0.52 0.67 1.71
ABD-400b 400 100.6 6 0.72 99.95 6 0.86 1.30 1.43
Bandy-400c 400 101.8 6 0.71 102.3 6 0.89 0.98 1.57
aMarketed by Medopharm Pvt. Ltd., Malur, Karnataka, India. 
bIntas Pharmaceuticals Ltd., Ahmedabad, Gujarat, India.
cMankind Pharma Ltd., New Delhi, India.
dMean value of five determinations. Tabulated t-value and F-value at 95% confidence level is 2.78 and 6.39.
4.1. Recovery study
A standard addition procedure was followed to further evaluate the accuracy of the method. The solutions were 
prepared by spiking pure drug into a pre-analyzed tablet powder at three different levels and injected to chromato-
graphic column. The recovery of the known amount of added analyte was computed. The percentage recovery of ALB 
from tablet ranged 99.6–101.4%. The results given in Table 9 reveal good accuracy of the proposed method.
Table 9: Results of recovery study by standard addition method.
Tablets studied
ALB in tablet 
(mg mL21)




Pure ALB  
recovered % 6 SD*
Alworm-400
19.96 10.0 29.83 99.6 6 1.68
19.96 20.0 40.48 101.3 6 0.86
19.96 30.0 50.26 100.6 6 1.58
ABD-400
19.99 10.0 30.11 100.4 6 0.80
19.99 20.0 40.47 101.2 6 1.57
19.99 30.0 49.84 99.7 6 0.66
Bandy-400
20.36 10.0 30.78 101.4 6 0.80
20.36 20.0 39.92 98.9 6 1.36
20.36 30.0 50.71 100.7 6 0.92
*Mean value of three determinations.
5. Conclusion
A stability indicating reverse phase UHPLC method was developed for the determination of ALB in bulk drug and 
in tablets. The experimental design describes the scouting of the key UHPLC method components including column, 
pH and mobile phase. Their interrelationships are studied and the preliminary optimized conditions are obtained 
for each combination of column, pH and mobile phase. Here, a better understanding of the factors influencing chro-
matographic separation and greater confidence in the ability of the method to meet its intended purposes is done. 
The proposed method is simple, rapid, precise, accurate, specific and selective. The retention time obtained (2.24 min) 
enables rapid determination of the drug which is important in routine analysis. Degradation study of the method 
reveals that the product is stable in photolytic, hydrolytic and elevated temperature; slightly stable in acidic and highly 
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unstable in basic and oxidative medium. This method exhibited an excellent performance in terms of sensitivity and 
speed. The validation results were found to be satisfactory and hence, this method can be used for quality control and 
stability assessment of ALB in bulk drug and tablet forms.
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